Jeremy Sohn
General Partner at P74 Ventures
Boston, Massachusetts
Overview
Work Experience
Board Member
2024 - Current
Member of the Board of Directors.
Managing Partner
2023
P74 Bio is a novel credit fund that has the safety profile of a government-backed treasury, but the target-return profile of VC/PE. P74 Bio lends to clinical-stage biotech companies (Phase I-III) that want access to non-dilutive capital to run a clinical trial. The Fund leverages an Australian-sponsored tax rebate program that effectively operates as a cash credit to both securitize and offset the cost of the debt. Principal is repaid and recycled annually from the rebate program. The Fund is an expansion of P74’s anchor investor’s (SPRIM’s) existing investment strategy.
Managing Partner
2022
P74 Ventures is uniquely positioned to be the leading Pharma-Tech venture fund -- focused on both founding and investing in technology companies that drive innovation and business model transformation within the $1.5 trillion life sciences industry. Although pharma is transforming how we treat disease, drug costs, patient access, and HCP awareness remain the largest obstacles to improving health & wellness. Technology-driven business innovation is critical to eliminate these obstacles. In fact, pharma-tech has the potential to multiply the impact of scientific breakthroughs and save billions of more lives. But most healthcare VCs focus on either biotech or the broader digital health landscape. And few VCs have the expertise to invest in the enabling technologies that drive the business & operations of pharma. Even fewer, have the ability to also co-found companies targeting the core challenges in this space. And, maybe most importantly, no other VCs have the executive-level pharma network to immediately create and unlock value for their portfolio companies. Together, P74’s Managing Partners have been at the forefront of pharma’s innovation efforts for the last decade – starting companies and leading digital investments, global innovation, strategic corporate partnerships, and data science and AI at the #3 pharma company in the world, Novartis. As leading experts in the field, P74’s Fund Managers believe they can continue to achieve alpha returns by investing in and/or co-founding early-stage companies targeting problems and markets where the Team has deep experience and where at least one pharma will be a founding partner, paying customer, and/or co-development collaborator. Over the last few years alone, the team has completed 26 investments (with 3 IPOs/SPACs & 5 unicorns), founded 3 companies (with 2 PE exits), led partnerships with over 85 startups and industry-leading tech companies, and developed 8 transformational technology platforms for big-pharma.
P74 Ventures is a venture capital firm that invests in in technology companies that drive innovation and business model transformation.
Venture Affiliate
2015
As a Venture Affiliate, I serve as a digital health and life-sciences advisor to Boston Millennia Partners.
Boston Millennia Partners provides private equity financing to high growth companies in the healthcare and business services industries.
Member of the Board
2016 - 2022
Jeremy served as a non-investor, independent Board Member for the Company.
NeuraSignal develops AI and robotics-enhanced medical tech for real-time cerebral blood flow monitoring.
Co-Head, Private Healthcare Ventures
2021 - 2022
Jeremy co-led Magnetar Capital's private healthcare venture investment efforts.
Magnetar Capital is an alternative asset manager that structures its investments to be profitable across a wide range of outcomes.
Chairman, Investment Committee
2018 - 2021
Since joining Novartis in 2015, Jeremy was responsible for overseeing the strategy, performance, investment team, and governance of dRx Capital, Novartis' data and digital health-focused venture Fund. Jeremy assumed Chairmanship of the Investment Committee in January 2018. The Fund invests in companies that achieve one or more of Novartis' core strategic goals: driving operational efficiency, transforming its current business model, improving access to healthcare, and/or reimagining the practice of medicine. Investments span every aspect of Novartis' business: from research and development, to manufacturing and supply chain, through commercial, medical, and patient care. Under Jeremy's leadership, the Fund invested in 21 portfolio companies, including: Omada Health, Science 37, Cala Health, Pear Therapeutics, Cota, Aktana, Freenome, Mekonos, SchoolCare, Xealth, NeuvoAir, Vineti, Animantis, Koneksa, H1 Insights, Peptone, RxVantage, Flywheel, AspenRx, SomaLogic, and DopaVision.
VP, Global Head of Digital BD&L, Partnerships, & Innovation
2015 - 2021
Jeremy was a member of the executive leadership teams for both the Chief Digital Office and Global BD&L / M&A and was responsible for advising, executing, and overseeing Novartis’ data & digital strategy and transformation, globally and cross-divisionally. Jeremy’s responsibilities cover 4 main areas: (1) Partnerships: Jeremy’s team was responsible for implementing & overseeing our global data and technology partnerships, including Amazon, Microsoft, Tencent, Google, Concert.ai, and Pear. (2) Venture investments: Jeremy oversaw and managed Novartis' digital investments, including dRx Capital, a $100M digital-health focused venture capital fund. Representative investments include Science 37, Omada, Freenome, Aktana, Cala Health, H1 Insights, AspenRx, and SomaLogic. (3) Ecosystem development & digital acceleration: Jeremy oversaw multiple initiatives to strengthen Novartis reach within the global technology community, including the Novartis’ BIOME, our Startup Health partnership, and our HealthX World Series events. (4) Strategy development & new business model exploration: Jeremy worked closely with Novartis' Corporate Strategy teams leading and/or advising multiple efforts to explore new technologies & business models. Jeremy has been a keynote speaker for multiple industry conferences including Medidata Next 2018, SCOPE 2017, CES Summit 2016, Qualcomm Connect 2016, the Korea-Swiss Life Sciences Summit 2016, and many others.
Global Head of Commercial Digital Medicines
2017 - 2018
In addition to his role in BD&L, Jeremy also served as ad-interim Global Head of Commercial Digital Medicines, managing a team of digital medicine and digital marketing leads within each of Novartis' global Pharma franchises. In this role, Jeremy was responsible for overseeing and advising the key strategic digital-innovation programs within each of our global brands.
Global Head of Digital Development
2016 - 2016
In 2016, in addition to his role in BD&L, Jeremy also served as the Global Head of Digital Development, Novartis' clinical innovation and operation excellence team. In this role, Jeremy helped Novartis lead the industry in terms of implementation scale for multiple innovation initiatives, including eICF, eSource, patient-engagement, BYOD, connected sensors, and decentralized studies.
Board Observer
2016 - 2021
Jeremy served as the Novartis Board Observer.
Bringing clarity to cancer. Working to ensure that everyone touched by cancer has a clear path to the right care.
Raised $109,000,000.00 from Deerfield.
Board Observer
2016 - 2021
Jeremy served as the Novartis Board Observer.
Education
BA
1993 - 1997
High School Diploma, Co-Valedictorian
1988 - 1992